Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study.
dc.contributor.author | Eadon, Michael T. | |
dc.contributor.author | Maddatu, Judith | |
dc.contributor.author | Moe, Sharon M. | |
dc.contributor.author | Sinha, Arjun D. | |
dc.contributor.author | Ferreira, Ricardo Melo | |
dc.contributor.author | Miller, Brent W. | |
dc.contributor.author | Sher, S. Jawad | |
dc.contributor.author | Su, Jing | |
dc.contributor.author | Pratt, Victoria M. | |
dc.contributor.author | Chapman, Arlene B. | |
dc.contributor.author | Skaar, Todd C. | |
dc.contributor.author | Moorthi, Ranjani N. | |
dc.date.accessioned | 2022-09-27T15:51:19Z | |
dc.date.available | 2022-09-27T15:51:19Z | |
dc.date.issued | 2022-02 | |
dc.description.abstract | BACKGROUND: Patients with CKD often have uncontrolled hypertension despite polypharmacy. Pharmacogenomic drug-gene interactions (DGIs) may affect the metabolism or efficacy of antihypertensive agents. We report changes in hypertension control after providing a panel of 11 pharmacogenomic predictors of antihypertensive response. METHODS: A prospective cohort with CKD and hypertension was followed to assess feasibility of pharmacogenomic testing implementation, self-reported provider utilization, and BP control. The analysis population included 382 subjects with hypertension who were genotyped for cross-sectional assessment of DGIs, and 335 subjects followed for 1 year to assess systolic BP (SBP) and diastolic BP (DBP). RESULTS: Most participants (58%) with uncontrolled hypertension had a DGI reducing the efficacy of one or more antihypertensive agents. Subjects with a DGI had 1.85-fold (95% CI, 1.2- to 2.8-fold) higher odds of uncontrolled hypertension, as compared with those without a DGI, adjusted for race, health system (safety-net hospital versus other locations), and advanced CKD (eGFR <30 ml/min). CYP2C9-reduced metabolism genotypes were associated with losartan response and uncontrolled hypertension (odds ratio [OR], 5.2; 95% CI, 1.9 to 14.7). CYP2D6-intermediate or -poor metabolizers had less frequent uncontrolled hypertension compared with normal metabolizers taking metoprolol or carvedilol (OR, 0.55; 95% CI, 0.3 to 0.95). In 335 subjects completing 1-year follow-up, SBP (-4.0 mm Hg; 95% CI, 1.6 to 6.5 mm Hg) and DBP (-3.3 mm Hg; 95% CI, 2.0 to 4.6 mm Hg) were improved. No significant difference in SBP or DBP change were found between individuals with and without a DGI. CONCLUSIONS: There is a potential role for the addition of pharmacogenomic testing to optimize antihypertensive regimens in patients with CKD. | en_US |
dc.identifier.citation | Eadon, M. T., Maddatu, J., Moe, S. M., Sinha, A. D., Ferreira, R. M., Miller, B. W., Sher, S. J., Su, J., Pratt, V. M., Chapman, A. B., Skaar, T. C., & Moorthi, R. N. (2022). Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. Kidney360, 3(2), 307–316. https://doi.org/10.34067/kid.0005362021 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/30132 | |
dc.language.iso | en | en_US |
dc.publisher | American Society of Nephrology | en_US |
dc.relation.isversionof | 10.34067/kid.0005362021 | en_US |
dc.subject | Hypertension/complications | en_US |
dc.subject | Renal Insufficiency, Chronic/complications | en_US |
dc.subject | Cross-Sectional Studies | en_US |
dc.title | Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. | en_US |
dc.type | Article | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Eadon2022Pharmacogenomic-preprint.pdf
- Size:
- 339.9 KB
- Format:
- Adobe Portable Document Format
- Description:
- Preprint
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.99 KB
- Format:
- Item-specific license agreed upon to submission
- Description: